Issue Date: February 22, 2016 | Web Date: February 18, 2016
Pliant Launches To Tackle Fibrotic Diseases
Another biotech firm is debuting with a hefty first round of financing. Rooted in work emerging from four labs at the University of California, San Francisco, Pliant Therapeutics is launching with $45 million in Series A funding from the venture capital firm Third Rock Ventures to develop treatments for fibrotic disorders.
Pliant is the result of several years of work by life sciences-focused Third Rock, which wanted to tap into a surge in research related . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society